Scarica l'app Stockscreener
28.09
0.74%
-0.21
Dopo l'orario di chiusura:
28.12
0.03
+0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
24,909 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Affinity Investment Advisors LLC - MarketBeat
PFIZER INC : UBS reiterates its Neutral rating - Marketscreener.com
Leerink Partnrs Weighs in on Pfizer's Q4 Earnings (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Shares Bought by Lincluden Management Ltd. - MarketBeat
Pfizer (NYSE:PFE) Upgraded at Evercore ISI - MarketBeat
Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Simply Wall St
Pfizer faces lawsuit over withdrawn sickle cell drug - Daily Journal
Pfizer Inc. (NYSE:PFE) Director Acquires $28,240.00 in Stock - MarketBeat
Is Pfizer (NYSE:PFE) a High-Yielding Dividend Stock Worth Buying? - Yahoo Finance
Pfizer director Scott Gottlieb purchases $28,240 in common stock - Investing.com
Pfizer sees strong Q3, led by revenues for Covid vaccine, Paxlovid - Healthcare Brew
Pfizer: Overstated Pessimism Makes Little Sense (NYSE:PFE) - Seeking Alpha
Pfizer presents new AMPK activators - BioWorld Online
Zacks Investment Ideas feature highlights: Pfizer, Philip Morris and Tenet Healthcare - Zacks Investment Research
Is Pfizer Stock A Sell After Covid Products Drive Surprise Upside? - Investor's Business Daily
Cantor Fitzgerald Boosts Earnings Estimates for Pfizer - MarketBeat
Results: Pfizer Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Pathway Financial Advisers LLC Sells 17,982 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
3 Factors That Make Pfizer's Ultra-High-Yield Dividend Safer Than You Might Think - Yahoo Finance
Diclofenac Patches Market Is Booming Worldwide 2024-2031 | - openPR
Pfizer Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Pfizer Covid sales boost prompts durability concernsBank of America - Proactive Investors USA
Pfizer (NYSE:PFE) Stock Price Down 0.7%Here's What Happened - MarketBeat
Pfizer boasts over 30% increase in Q3 revenues against previous year - Yahoo Finance
Goldman Sachs raises Pfizer stock target, keeps buy rating on Paxlovid sales - Investing.com
Pfizer Surpasses Q3 Expectations with Strong Earnings and Revenue Surge - Yahoo Finance
Golden State Equity Partners Invests $1.04 Million in Pfizer Inc. (NYSE:PFE) - MarketBeat
Here's Why Pfizer (PFE) is a Strong Value Stock - Yahoo Finance
Pfizer Inc. Reports Strong Q3 2024 Results, Raises Guidance - MSN
Are Wall Street Analysts Predicting Pfizer Stock Will Climb Or Sink? - Barchart
Pfizer Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Pfizer (PFE) PT Raised to $33 at Goldman Sachs - StreetInsider.com
PFIZER INC. (PFE) - MSN
Pfizer reports Q3 2024 net income of $4.46bn - World Pharmaceutical Frontiers
Is Eli Lilly Stock a Buy? - The Motley Fool
Pfizer Inc (PFE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance - Yahoo Finance
Pfizer rebuffs Starboard criticism as it raises forecasts - pharmaphorum
Pfizer’s earnings crush estimates as company raises guidance - MSN
Pfizer (PFE) Stock Movement Driven by Activist Investor Concerns - GuruFocus.com
Why Pfizer Stock Tumbled on Tuesday - Yahoo Finance
Pfizer CEO on company's 'exceptional quarter' & Starboard fight - Yahoo Finance
Health Care Flat as Pfizer Weighs -- Health Care Roundup - Marketscreener.com
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Pfizer Braces for Activist Battle With Forecast Increase - MSN
Pfizer Earnings: Maintaining Our Valuation as Management Pressed for Evidence of Productivity - Morningstar
Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure - Yahoo Finance
Pfizer CEO defends performance after Starboard activist criticism - Financial Times
Pfizer CEO Defends Record Against Activist Attack - Barron's
Pfizer CEO: The activist investors are 'too late' - Yahoo Finance
Pfizer sales of RSV vaccine ebb, but company gains market share - BioPharma Dive
Pfizer’s Bourla Defends Strategy In The Wake Of Starboard’s Activist Investment - Scrip
Pfizer’s Oncology Triumphs Keep Investors Hooked Amid Market Volatility - Seeking Alpha
Pfizer (PFE) Raises Forecast, Braces for Fight With Starboard - Bloomberg
Pfizer CEO, Under Fire, Will Do ‘Whatever It Takes’ to Grow (1) - Bloomberg Law
Pfizer’s Strong Quarter Bolsters CEO’s Comeback Efforts - The Wall Street Journal
Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor - Investopedia
Pfizer (NYSE:PFE) Shares Down 2.4%What's Next? - MarketBeat
Key takeaways from Pfizer’s (PFE) Q3 2024 earnings report - AlphaStreet
Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed - Seeking Alpha
Trending : Pfizer Raises Guidance After Strong 3Q - Marketscreener.com
Trending: Pfizer Raises Guidance After Strong 3Q - Morningstar
Why is Pfizer stock falling after Q3 results? (PFE:NYSE) - Seeking Alpha
Pfizer rides Paxlovid sales growth to better than expected third quarter - CNA
Pfizer’s guidance bump will not heal deeper wounds - Financial Times
Pfizer CEO, Under Fire, Will Do ‘Whatever It Takes’ to Grow | Company Business News - Mint
Ford Q3 earnings, Pfizer outlook amid Starboard fight: Morning Brief - Yahoo Finance
Pfizer CEO defends turnaround strategy as activist pressures management - Reuters
Nasdaq Surges Over 100 Points; Pfizer Earnings Top ViewsPfizer (NYSE:PFE) - Benzinga
0.29%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):